Axsome Therapeutics showcased new clinical data on SYMBRAVO, their migraine treatment combining meloxicam and rizatriptan, at the American Headache Society's 68th Annual Scientific Meeting. The presentations covered efficacy, safety, and comparative analyses with other migraine treatments, highlighting sustained pain relief and functional recovery. This data reinforces SYMBRAVO's potential in acute migraine care and supports Axsome's ongoing mission to advance CNS disorder treatments. Further developments and regulatory progress are anticipated as Axsome continues clinical trials and product launches.
Clean Energy Fuels Corp. has launched its eighth dairy renewable natural gas (RNG) facility at East Valley Cattle in Jerome, Idaho, one of North America's largest dairies. The facility processes over 5 million gallons of manure daily using advanced t...
Broadcom's CEO confirmed a bold forecast of over $100 billion in AI semiconductor revenue for fiscal year 2027, following a 180% revenue jump to $56 billion in 2026. The company has extended customer commitments through 2028, reflecting strong demand...
Auddia Inc. has started developing the McCarthy Finney Operating System (MCFN-OS), an AI-native, Web3-enabled platform designed to automate workflows and support multiple subsidiaries with agentic AI and blockchain trust. The first production module ...
US Signal is significantly expanding its Aurora, Illinois data center to increase power capacity and resiliency, supporting growing enterprise needs for hybrid cloud, AI infrastructure, and data protection. The multi-phase upgrade will more than doub...
Girard Sharp LLP is investigating potential securities claims for former investors of Blue Owl Capital Corp. III and Blue Owl Technology Finance Corp. II after their shares were converted in mergers in early 2025. Since the mergers, Blue Owl Capital'...
